Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547740 · ClinicalTrials.gov registry record
Macular Damage in Early Glaucoma and Progression
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 260
- Enrollment target
NCT02547740 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 260 participants.
The verdict
NCT02547740 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 260 participants
- Enrollment target
Study Summary
Glaucoma is the leading cause of irreversible blindness worldwide. This study aims to test a new method that may allow earlier diagnosis of glaucoma and better ways to monitor if it is getting worse. There is scientific evidence that the macula, the central part of the retina, can be involved in very early stages of glaucoma. Glaucomatous damage to the macula is very prevalent and is often missed using conventional clinical tests. Relatively little is known about progression of early glaucoma damage and its effects on the macula. This project investigates the nature of progressive damage to the macula and proposes new methods to improve accuracy to detect clinically significant progression.The study will evaluate the nature of damage to the macula's structures through OCT imaging and eye function via visual field tests.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2015-10 |
| Est. Completion | 2024-01-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02547740
The ClinicalTrials.gov registry entry for NCT02547740 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02547740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02547740 about?
NCT02547740 is a clinical study titled "Macular Damage in Early Glaucoma and Progression". Glaucoma is the leading cause of irreversible blindness worldwide. This study aims to test a new method that may allow earlier diagnosis of glaucoma and better ways to monitor if it is getting worse. There is scientific evidence that the macula, the central part of the retina, can be involved in ver...
What is the current status of trial NCT02547740?
This trial is currently completed. The enrollment target is 260 participants. The study started on 2015-10. Estimated completion is 2024-01-18.
Who is sponsoring clinical trial NCT02547740?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.